# GLOW legal status and FDA 503A category — glow peptide access > GLOW legal status: the glow peptide constituents are FDA Category 2 bulk substances, so compounding access is restricted. Access is under active FDA review and may expand in 2026 — cited to FDA. Access to GLOW's peptide constituents is under active FDA review and may expand in 2026 — but as the record stands today they are FDA Category 2 bulk substances, and compounding access is restricted. The present-tense facts, cited to FDA. ## GLOW legal status: where peptide access stands, and where it is heading GLOW legal status turns on its constituents, and the most important context is forward-looking: access to these peptides is under active FDA review and may expand in 2026. The U.S. Food and Drug Administration has scheduled a Pharmacy Compounding Advisory Committee (PCAC) meeting for July 23-24, 2026 to discuss BPC-157 and TB-500 as candidates "being considered for inclusion on the 503A Bulks List" [13]. That is a scheduled evaluation of substances under review — momentum in the process — not a decision, a reclassification, or a dated outcome. As the record stands today, the present-tense fact is narrower. GLOW's injectable peptide constituents are research peptides that FDA placed in its 503A "Category 2" — bulk substances FDA has identified as raising significant safety risks — effective with the September 29, 2023 update to the nominated-substances list [12]. Category 2 substances are not covered by the enforcement-discretion policy that applies to Category 1, so compounding-pharmacy access to them is currently restricted [11][12]. This page is general information about the regulatory landscape, not medical or legal advice, and not an offer to supply any substance. ## The 503A and 503B framework, in brief Two sections of the Federal Food, Drug, and Cosmetic Act govern compounding. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies, federal facilities, and licensed physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that may compound larger batches under cGMP-style oversight and FDA registration and inspection [11]. A compounder may use a bulk drug substance — an active ingredient used as a starting material, rather than a finished FDA-approved drug — only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list [11]. Substances not yet on a bulks list are evaluated through a public nomination process with input from PCAC. Being discussed by PCAC is a step in that evaluation, not a final listing decision [11][13]. None of GLOW's three peptide constituents is an FDA-approved drug. ## Where each GLOW constituent stands today **BPC-157.** FDA identified BPC-157 as a bulk drug substance that may present significant safety risks and placed it in Category 2 for 503A compounding, effective with the September 29, 2023 update, citing concerns including potential immunogenicity for certain routes and complexities with peptide-related impurities and characterization [12]. As a Category 2 substance it is not within FDA's enforcement-discretion policy. BPC-157 is on the published agenda of the July 23-24, 2026 PCAC meeting as a substance being considered for the 503A bulks list — a scheduled discussion, not a change in current status [13]. **TB-500 (thymosin beta-4 fragment).** FDA identified "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" as a bulk substance that may present significant safety risks and placed it in Category 2, effective with the same September 29, 2023 update, citing immunogenicity concerns for certain routes and a lack of important safety information [12]. FDA's own list entry establishes that TB-500 is the LKKTETQ fragment associated with thymosin beta-4. TB-500 also appears on the July 23-24, 2026 PCAC agenda as a candidate under evaluation [13]. **GHK-Cu (copper peptide).** Two regulatory contexts must be kept separate. As a cosmetic, GHK-Cu is labeled "Copper Tripeptide-1" and used as a topical ingredient; cosmetic ingredients are regulated under cosmetics rules and are not subject to FDA pre-market drug approval [15]. As an injectable drug, FDA identified "GHK-Cu (for injectable routes of administration)" as a bulk substance that may present significant safety risks and placed it in Category 2, effective with the September 29, 2023 update [12]. Injectable GHK-Cu is not on the July 23-24, 2026 PCAC agenda, and its injectable form remains Category 2 — separate from the legal cosmetic Copper Tripeptide-1 [13]. ## How legally compounded peptide access works Where a substance is eligible for compounding, the lawful access path follows a fixed order. First, a patient is evaluated by an appropriately licensed prescriber — in person or via a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate [11]. Telehealth is one channel for that prescriber-evaluation step; it is a route to a licensed-prescriber consultation, not a separate legal status, and it does not expand which substances may be compounded [11]. If the preparation is appropriate and lawful, the prescriber issues a valid, patient-specific prescription. That prescription is then dispensed by a state-licensed 503A compounding pharmacy (patient-specific) or, for office and batch use, sourced from an FDA-registered 503B outsourcing facility [11]. The ingredient-eligibility caveat governs the whole path: the compounder may use the requested active ingredient only if it is eligible under the 503A/503B bulk-substance rules, and ingredients FDA has flagged for significant safety risks are not eligible for routine 503A compounding while that status stands [11][12]. This is general information; it is not a description of how to obtain a restricted substance. --- The GLOW peptide record, set in plain type — three constituent literatures read for what they show and where they stop, prescribed by no clinic and sold by no one.